Clinical trial · Interventional
The Clinical Validity and Safety of IOP Injection MRI Contrast Agent in Hepatocellular Carcinoma
A Phase II, Multi-Center, Open-Label, Single-Arm Study to Evaluate the Clinical Validity and Safety of IOP Injection for Magnetic Resonance Imaging (MRI) Contrast Agent in Hepatocellular Carcinoma (HCC)
NCT03407495CI-TRIAL-00054611completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is an exploratory study aiming to collect data on sensitivity and positive predictive value of IOP-enhanced (MPB-1523) MRI compared to dynamic multiphase MDCT for the detection of HCC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Magnetic Resonance Imaging | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| IOP Injection (MPB-1523) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- single arm: IOP injection (MPB-1523)
- description
- single group treatment
- interventionNames
- Drug: IOP Injection (MPB-1523)
Primary outcomes (1)
- measure
- The Sensitivity and specificity of IOP-enhanced MRI
- timeFrame
- After IOP injection administration within 60 mins
- description
- Sensitivity and specificity of IOP-enhanced MRI will be calculated using dynamic multiphase MDCT as the reference standard. Confirmation of the diagnosis of HCC lesions will be obtained by surgery.
Secondary outcomes (3)
- measure
- Optimal time to perform a MRI scan after injection of IOP
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Subjects ≥18 years of age 2. Patients with suspected HCC scheduled for partial hepatic resection. 3. Presenting with 1 to a maximum of 5 hepatic nodule(s) of equal or more than 1 cm (long axis) previously identified and characterized through multi-phase contrast enhanced CT. 4. Subjects or their partners must use a highly effective method of contraception starting from at least one menstrual cycle prior to starting study drug and till 30 days after the last dose of study drug. Exclusion Criteria: 1. Subjects who received any previous treatment for HCC. 2. Subjects with a serious allergic history or known allergy of other contrast agent. 3. Subjects with a positive HIV test. 4. Subjects with severe renal insufficiency 5. Subjects with severe liver disease\[HCV\]. 6. Subjects with active systemic infections, active and clinically significant cardiac diseases, active gastrointestinal ulcers, or medical conditions that may significantly affect action, adequate absorption, and elimination of investigational contrast agent. 7. Subject with mechanically, electrically or magnetically-activated implanted device or any metal in their body which cannot be removed. 8. Subjects who have participated in other investigational trials within 30 days prior to study enrollment. 9. Female subjects who are pregnant or breastfeeding. 10. Subjects who are clinically unstable and whose clinical course during the screening period is unpredictable.
References
Publications (0)
Data not yet available
No reference posted for this study.